Sanofi is a research and development-driven biopharmaceutical company that discovers, develops, and delivers medicines and vaccines. The company focuses on therapeutic areas including immunology, oncology, rare diseases, and vaccines, leveraging artificial intelligence to accelerate drug discovery. Sanofi operates globally, serving patients and healthcare systems worldwide. The company maintains strategic alliances with partners such as Regeneron and Cheplapharm to expand its portfolio of next-generation immunology antibodies and mature medicines. Sanofi also collaborates with Ablynx for research and development activities. The group manages a pipeline of compounds in clinical development, including multiple phase 3 trials, to address unmet medical needs in chronic skin diseases, multiple sclerosis, and other conditions.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Drug Manufacturers - General Homepage sanofi.com
Sector Healthcare IR page sanofi.com/en/investors
Tags
biopharmaceuticals, vaccines, immunology, oncology, rare diseases, drug discovery, artificial intelligence, clinical trials, autoimmune diseases, multiple sclerosis, Ablynx, Regeneron, Cheplapharm, ITP Control Tool
Press page sanofi.com/en/media-room/press-releases

Metrics

Valuation  
Market cap € 97.56B
Market cap (USD) $ 107.209B
P/E 19.75
PEG —
P/BV 1.36
P/S 2.24
P/OCF 9.08
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE 10.4%
ROI 9.1%
ROIC 5.5%
Profit margin 17.9%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) -16.0%
Quality  
Profitable Yes
Margin expanding No
Buying back stock Yes
Diluting (TTM) No
Debt/Equity 19.9%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 171
Quality score 29.4%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010
Revenue 43.626B 41.081B 43.07B 42.997B 37.761B 36.041B 36.126B 6.143B — — 35.058B —
Net profit 7.813B 5.56B 5.4B 8.371B 6.223B 12.314B 2.806B 4.509B — — 5.934B —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010
Share price 91.3 53.12 92.54 91.34 87.7 — — — — — — —
Price performance 12m 0.72 -0.43 0.01 0.04 — — — — — — — —

Filed figures

Figure Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (EUR) — 7.26B 7.94B 7.49B 7.57B 8.42B 8.43B 7.68B 8.41B
↳ YoY growth +9.3% -5.6% +1.0% +11.3% +0.1% -9.0% +9.5%
↳ 5y CAGR +3.0% -0.7% +2.3%
Other receivables (EUR) — — — — 805M 1.29B 1.45B 1.45B 1.48B
Borrowings, current (EUR) — 2.63B 4.55B 2.77B 3.18B 4.17B 2.05B 4.21B 4.34B
Borrowings, non-current (EUR) — 22B 20.1B 19.7B 17.1B 14.9B 14.3B 11.8B 14.2B
Lease liabilities (EUR) — 0.00 1.25B 1.16B 2.11B 2.18B 2.03B 1.91B 1.74B
Cash and deposits (EUR) 10.3B 6.93B 9.43B 13.9B 10.1B 12.7B 8.71B 7.44B 7.66B
Intangible assets (EUR) — 21.9B 16.6B 18.4B 21.4B 21.6B 24.3B 22.6B 26.3B
Right-of-use assets (EUR) — 0.00 1.3B 1.2B 1.95B 1.82B 1.65B 1.51B 1.46B
Net debt (borrowings + leases - cash) (EUR) — 17.7B 16.5B 9.76B 12.3B 8.48B 9.71B 10.5B 12.7B
Cash flow detail
Operating cash flow (EUR) — 5.55B 7.74B 7.45B 10.5B 10.5B 10.3B 9.08B 10.8B
Purchases of property, plant and equipment (EUR) — -1.98B -1.82B -2.11B -2.04B -2.2B -3.02B -3.2B -3.54B
Change in receivables (cash effect) (EUR) — -35M -462M -134M 185M -777M -397M -28M -1.2B
Change in inventories (cash effect) (EUR) — -701M -547M -593M -357M -927M -840M -477M -39M
Change in payables (cash effect) (EUR) — 270M 169M 86M 451M 452M 402M 789M 398M
Dividends paid (cash effect) (EUR) — -3.77B -3.83B -3.94B -4.01B -4.17B -4.45B -4.7B -4.77B
Share buybacks (cash effect) (EUR) — -1.1B -9M -822M -382M -497M -593M -302M -5.03B
Interest paid (cash effect) (EUR) — -313M -379M -315M -334M -380M -559M -587M -485M
Income taxes paid (cash effect) (EUR) — -2.06B -1.7B -2.05B -1.28B -2.45B -2.62B -3.29B -2.89B
Share-based compensation (EUR) — 284M 252M 274M 244M 245M 283M 278M 313M
Operating cash flow before change in receivables (EUR) — 5.58B 8.21B 7.58B 10.3B 11.3B 10.7B 9.11B 12B
Free cash flow (OCF - PPE - intangibles) (EUR) — 3.57B 5.93B 5.34B 8.48B 8.33B 7.23B 5.89B 7.21B
Income detail
Research and development expense (EUR) — 5.89B 6.02B 5.53B 5.69B 6.71B 6.73B 7.39B 7.84B
↳ 5y CAGR +2.7% +4.2% +7.2%
Total comprehensive income (EUR) — 5.37B 3.49B 8.34B 9.59B 11.2B 3.83B 8.05B 3.16B
Comprehensive income to owners (EUR) — 5.27B 3.46B 8.32B 9.52B 11.1B 3.81B 7.97B 3.17B
Reported Mar 4, 2021 Mar 4, 2021 Mar 4, 2021 Mar 4, 2021 May 15, 2024 May 15, 2024 May 15, 2024 Feb 17, 2026 Feb 17, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

FY 2026: guidance upgraded

October 30, 2026

Q3 sales growth of 14.3% at CER1 and business earnings per share (EPS)2 of €3.55

•Pharma launches sales increased by 31.4%, reaching €1.4 billion, driven by ALTUVIIIO, Ayvakit, and Rezurock

•Dupixent sales increased by 34.8% to €5.7 billion, above €5 billion per quarter for the second time

•Vaccines sales decreased by 6.6% to €3.2 billion, impacted by the anticipated phasing in respiratory prevention

•Research and Development expenses reached €1.8 billion, broadly stable

•Selling and general expenses reached €2.3 billion, down by 0.9%, reflecting cost discipline

•Business EPS was €3.55, up by 19.6% at CER; 22.0% at actual exchange rates; IFRS EPS €2.52

Pipeline update

•Two regulatory approvals; in rare diseases and vaccines

•One regulatory submission acceptance and two regulatory designations (priority review and PRIME)

Guidance upgraded

•2026 guidance is upgraded: sales are expected to grow by a low-teens percentage at CER.

October 30, 2026

Download PDF

Share

Q3 2026: double-digit growth in sales and business EPS FY 2026: guidance upgraded

October 30, 2026

Q3 sales growth of 14.3% at CER1and business earnings per share (EPS)2of €3.55

  • Pharma launches sales increased by 31.4%, reaching €1.4 billion, driven by ALTUVIIIO, Ayvakit, and Rezurock

  • Dupixent sales increased by 34.8% to €5.7 billion, above €5 billion per quarter for the second time

  • Vaccines sales decreased by 6.6% to €3.2 billion, impacted by the anticipated phasing in respiratory prevention

  • Research and Development expenses reached €1.8 billion, broadly stable

  • Selling and general expenses reached €2.3 billion, down by 0.9%, reflecting cost discipline

  • Business EPS was €3.55, up by 19.6% at CER; 22.0% at actual exchange rates; IFRS EPS €2.52

Pipeline update

  • Two regulatory approvals; in rare diseases and vaccines

  • One regulatory submission acceptance and two regulatory designations (priority review and PRIME)

Guidance upgraded

  • 2026 guidance is upgraded: sales are expected to grow by a low-teens percentage at CER. Business EPS at CER is expected to grow by a mid-teens percentage.3

Belén Garijo, Chief Executive Officer: “Sanofi achieved another strong quarter with double-digit sales growth of 14.3%, mainly driven by our new medicines and Dupixent. Business EPS increased by 19.6%, driven by cost discipline. The pipeline milestones included two regulatory approvals, one regulatory submission, and two additional regulatory designations. Our strong commercial and financial momentum to date leads us to raise our 2026 guidance: sales growth is now expected at a low-teens percentage and business EPS growth at a mid-teens percentage, underscoring our sustainable, profitable growth.

In the third quarter, we accelerated Sanofi’s transformation by expanding our long-standing alliance with Regeneron, which opens up further opportunities in immunology. We also continued to simplify our portfolio through a partnership with Cheplapharm covering a number of legacy medicines4.

We are confident about our ability to pursue our strong commercial and financial performance in the short and medium term. The whole organisation is focused on managing Sanofi’s post-Dupixent trajectory over the next decade. Our priority is to protect earnings through Dupixent’s loss of exclusivity. We have already begun taking action to improve R&D productivity. Business development and M&A will be critical to complement this transformation. We remain committed to our long-term capital allocation policy, including our progressive dividend.”

| | Q3 2026 | Change | Change at CER | YTD 2026 | Change | Change at CER |

| Net sales | €14,444m | +16.2% | +14.3% | €36,550m | +13.1% | +15.2% |

| IFRS net income | €3,021m | +7.8% | — | €4,979m | -42.2% | — |

| IFRS EPS | €2.52 | +9.6% | — | €4.15 | -41.1% | — |

| Free cash flow5 | €3,269m | +9.2% | — | €6,993m | +28.3% | — |

| Business operating income | €5,430m | +22.2% | +19.7% | €11,688m | +19.2% | +21.1% |

| Business net income | €4,255m | +20.0% | +17.6% | €9,020m | +17.2% | +19.1% |

| Business EPS | €3.55 | +22.0% | +19.6% | €7.52 | +19.4% | +21.3% |

1 Changes in net sales are at constant exchange rates (CER) unless otherwise stated (see definition in Appendix 8). 2 To facilitate an understanding of operational performance, Sanofi comments on business operating income, business net income, and business EPS (bEPS), which are non-IFRS financial measures (see definitions in Appendix 8). The IFRS consolidated income statement is in Appendix 3, and a reconciliation of IFRS net income to business net income is in Appendix 4. 3 Applying October 2026 average currency exchange rates, currency impacts are estimated at c.-1% on sales and at c.-1% on business EPS. 4 Subject to information and consultation procedures with employee representatives, regulatory approvals, and customary closing conditions. 5 Free cash flow is a non-IFRS financial measure (see definition in Appendix 8).

Prompts

Sanofi (ticker SAN), listed in France.

Company History

Date Change Detail
Mar 29, 2023 Acquired Acquired Provention Bio, Inc. (Regulatory id 1695357). Its filings from before the deal are on its own company page, not shown here.
Sep 1, 2010 Renamed SANOFI-AVENTIS → SANOFI
Aug 31, 2004 Renamed SANOFI SYNTHELABO SA → SANOFI-AVENTIS

ETFs Holding Sanofi

ETF Weight in ETF Shares Market value As of
BINV 3.10% 177,082 $ 15.191M Jun 30, 2026
IDVZ 3.04% 138,907 $ 5.984M Jul 31, 2026
PAYR 2.91% 38,585 $ 1.662M Jul 31, 2026
GMOI 2.79% 434,143 $ 19.259M Aug 31, 2026
DTAN 2.25% 5,147 $ 490.39K Nov 17, 2026
BASV 2.19% 210,126 $ 8.964M Jun 30, 2026
TINS 2.15% 1,468 $ 126.012K Jun 30, 2026
DIVD 2.15% 12,312 $ 590K Nov 18, 2026
BUSA 2.07% 144,778 $ 6.176M Jun 30, 2026
DSTX 1.92% 10,559 $ 906.375K Jun 30, 2026
CVGD 1.92% 61,723 $ 2.659M Jul 31, 2026
FLV 1.55% 133,013 $ 5.9M Aug 31, 2026
GENW 1.39% 1,651 $ 71.125K Jul 31, 2026
BRIE 1.30% 91,224 $ 6.346M Aug 31, 2026
FENI 0.91% 1,435,818 $ 93.669M Jun 30, 2026
JHID 0.91% 1,152 $ 98.886K Jun 30, 2026
CGIC 0.91% 239,565 $ 23.266M Nov 16, 2026
TIIV 0.90% 6,875 $ 296.175K Jul 31, 2026
CGGO 0.89% 1,069,383 $ 103.855M Nov 16, 2026
UMMA 0.87% 28,654 $ 2.557M Aug 31, 2026
VDI 0.72% 1,377 $ 118.25K Jul 31, 2026
NBIE 0.70% 19,627 $ 1.751M Aug 31, 2026
AIVI 0.67% 4,561 $ 391.512K Jun 30, 2026
SEIE 0.64% 84,532 $ 7.256M Jun 30, 2026
IVSI 0.60% 551 $ 47.268K Jun 30, 2026
RINT 0.58% 9,400 $ 806.392K Jun 30, 2026
TOUS 0.56% 103,358 $ 8.9M Jul 31, 2026
RCGE 0.56% 5,832 $ 560K Nov 18, 2026
NTSI 0.41% 23,998 $ 2.06M Jun 30, 2026
APIE 0.40% 104,810 $ 4.649M Aug 31, 2026
AVSD 0.38% 28,969 $ 1.402M Nov 16, 2026
DFIV 0.37% 848,165 $ 82.569M Nov 12, 2026
QUIZ 0.33% 3,454 $ 308.24K Aug 31, 2026
DFAI 0.31% 585,199 $ 56.977M Nov 12, 2026
DFSI 0.27% 32,997 $ 3.213M Nov 12, 2026
AVDE 0.26% 1,060,595 $ 51.322M Nov 16, 2026
RGLO 0.21% 8,151 $ 699.245K Jun 30, 2026
IQSZ 0.19% 3,805 $ 326.916K Jul 31, 2026
TIER 0.17% 700 $ 60.278K Jul 31, 2026
GEW 0.16% 2,637 $ 235.269K Aug 31, 2026
RFDI 0.13% 2,577 $ 221.3K Jul 31, 2026
DFIC 0.12% 191,575 $ 18.614M Nov 12, 2026
DFAX 0.09% 106,992 $ 10.238M Nov 12, 2026
DXIV 0.06% 1,509 $ 146.921K Nov 12, 2026

Securities

Ticker Type Class Market Exchange Last price Price date
SNY Common share — US nasdaq 41.23 USD 2026-09-30
SAN canonical Common share — FR euronext 80.00 EUR 2026-10-30
SANNV Other NV26 FR euronext — —